非酒精性脂肪性肝病营养干预研究进展*

doi:10.3969/j.issn.1672-5069.2024.01.039

Abstract

Abstract: The nonalcoholic fatty liver disease (NAFLD) is the most common liver diseases worldwide. Currently, due to the lack of effective drugs for treatment of NAFLD, the scholars recommend reducing body weight and improving metabolism through dietary interventions. In this paper, we summarize the research progress of NAFLD-related dietary interventions and the mechanisms by which they play roles in therapeutic effects in order to better guide clinical practice.

Key words: Nonalcoholic fatty liver diseases, Nutritional intervention, Dietary strategies

Lin Ning, Kong Ming, Duan Zhongping. Nutritional intervention for patients with non-alcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2024, 27(1): 151-154.

References

[1] Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence,incidence,and outcomes.Hepatology,2016,64(1):73-84.
[2] 张薇,魏来.非酒精性脂肪性肝病在亚洲的流行情况.中华肝脏病杂志,2013,21(11):801-804.
[3] 中国研究型医院学会肝病专业委员会,中国医师协会脂肪性肝病专家委员会,中华医学会肝病学分会脂肪肝与酒精性肝病学组,等.中国脂肪性肝病诊疗规范化的专家建议(2019 年修订版).中华肝脏病杂志, 2019, 27(10): 748-753.
[4] Wattacheril J.Extrahepatic manifestations of nonalcoholic fatty liver disease.Gastroenterol Clin North Am,2020,49(1):141-149.
[5] Eslam M,Newsome PN,Sarin SK,et al.A new definition for metabolic dysfunction-associated fatty liver disease:An international expert consensus statement.J Hepatol,2020,73(1): 202-209.
[6] Nan Y,An J,Bao J,et al.The Chinese society of hepatology position statement on the redefinition of fatty liver disease.J Hepatol,2021,75(2): 454-461.
[7] Younossi ZM,Corey KE, Im JK.AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review.Gastroenterology,2021,160(3): 912-918.
[8] European association for the study of the liver (EASL),European association for the study of diabetes (EASD),European association for the study of obesity (EASO).EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.J Hepatol,2016, 64(6): 1388-1402.
[9] Eslam M, Sarin SK, Wong VW,et al.The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int,2020, 14(6): 889-919.
[10] Lu FB,Zheng KI,Rios RS,et al.Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol,2020, 35(12): 2041-2050.
[11] Tsompanaki E,Thanapirom K,Papatheodoridi M,et al.Systematic review and meta-analysis: The role of diet in the development of nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol,2023,21(6):1462-1474.
[12] Kirk E, Reeds DN, Finck BN, et al. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology, 2009, 136(5): 1552-1560.
[13] Browning JD, Baker JA, Rogers T, et al. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr, 2011, 93(5): 1048-1052.
[14] Johansson HE, Edholm D, Kullberg J, et al. Energy restriction in obese women suggest linear reduction of hepatic fat content and time-dependent metabolic improvements. Nutr Diabetes, 2019, 9(1): 34.
[15] Ma J, Hennein R, Liu C,et al. Improved diet quality associates with reduction in liver fat, particularly in individuals with high genetic risk scores for nonalcoholic fatty liver disease. Gastroenterology, 2018, 155(1): 107-117.
[16] Ryan MC, Itsiopoulos C, Thodis T,et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol, 2013, 59(1): 138-143.
[17] Properzi C, O'Sullivan TA, Sherriff JL,et al. Ad libitum Mediterranean and low-fat diets both significantly reduce hepatic steatosis: A randomized controlled trial. Hepatology, 2018, 68(5): 1741-1754.
[18] Ryan MC, Abbasi F, Lamendola C,et al. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care, 2007, 30(5): 1075-1080.
[19] Donnelly KL, Smith CI, Schwarzenberg SJ,et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest, 2005, 115(5): 1343-1351.
[20] Mozaffarian D, Hao T, Rimm EB,et al. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med, 2011, 364(25): 2392-2404.
[21] Summary for patients: Effect of calorie-unrestricted low-carbohydrate, high-fat diet versus high-carbohydrate, low-fat diet on type 2 diabetes and nonalcoholic fatty liver disease. Ann Intern Med, 2023, 176(1): I18.
[22] Parker A, Kim Y. The effect of low glycemic index and glycemic load diets on hepatic fat mass, insulin resistance, and blood lipid panels in individuals with nonalcoholic fatty liver disease. Metab Syndr Relat Disord, 2019, 17(8): 389-396.
[23] Tendler D, Lin S, Yancy WS Jr, et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci, 2007, 52(2): 589-593.
[24] Luukkonen PK, Dufour S, Lyu K, et al. Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2020, 117(13): 7347-7354.
[25] Rinaldi R, De Nucci S, Castellana F, et al.The effects of eight weeks' very low-calorie ketogenic diet (VLCKD) on liver health in subjects affected by overweight and obesity. Nutrients,2023, 15(4): 825.
[26] Cunha GM, Guzman G, Correa De Mello LL, et al. Efficacy of a 2-month very low-calorie ketogenic diet (VLCKD) compared to a standard low-calorie diet in reducing visceral and liver fat accumulation in patients with obesity. Front Endocrinol (Lausanne), 2020, 11: 607.
[27] Phillips SM, Chevalier S, Leidy HJ. Protein "requirements" beyond the RDA: implications for optimizing health. Appl Physiol Nutr Metab,2016, 41(5): 565-572.
[28] Campisano SE, Echarte SM, Podaza E, et al. Protein malnutrition during fetal programming induces fatty liver in adult male offspring rats. J Physiol Biochem, 2017, 73(2): 275-285.
[29] Bortolotti M, Kreis R, Debard C,et al. High protein intake reduces intrahepatocellular lipid deposition in humans. Am J Clin Nutr,2009, 90(4): 1002-1010.
[30] Markova M, Pivovarova O, Hornemann S, et al. Isocaloric diets high in animal or plant protein reduce liver fat and inflammation in individuals with type 2 diabetes. Gastroenterology, 2017, 152(3): 571-585.
[31] Torres-Peña JD, Arenas-de Larriva AP, Alcala-Diaz JF, et al. Different dietary approaches, non-alcoholic fatty liver disease and cardiovascular disease: a literature review. Nutrients, 2023, 15(6): 1483.
[32] Zeng X, Xie S, Jiang F,et al. Association between time-restricted eating and nonalcoholic fatty liver disease in a nationwide cross-sectional study. Br J Nutr, 2023, 27: 1-8.
[33] Wei X, Lin B, Huang Y, et al. Effects of time-restricted eating on nonalcoholic fatty liver disease: The TREATY-FLD randomized clinical trial.JAMA Netw Open,2023,6(3): e233513.
[34] Johari MI,Yusoff K,Haron J,et al.A randomised controlled trial on the effectiveness and adherence of modified alternate-day calorie restriction in improving activity of non-alcoholic fatty liver disease.Sci Rep,2019,9(1):11232.
[35] Holmer M,Lindqvist C,Petersson S,et al.Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial.JHEP Rep,2021,3(3):100256.

Nutritional intervention for patients with non-alcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Guo Meng, Guo Qi, Zhang Feng. Evaluation of hepatic steatosis by controlled attenuation parameter of ultrasonic transient elastography in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2024, 27(2): 189-192.
[2]	Huang Jiejie, Zheng Qian, Lyu Rui, et al. Efficacy of liraglutide and atorvastatin calcium combination in treating patients with nonalcoholic fatty liver diseases complicated with abnormal glucolipid metabolism [J]. Journal of Practical Hepatology, 2024, 27(1): 36-39.
[3]	Hou Yilin, Cao Fenghua, Ji Xiaoyan, et al. Changes of intestinal flora as well as serum interliukin-17 and interferon-γ levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 819-822.
[4]	Han Shishan, Zhao Caiyan. Perspective of betatrophin in the development of nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 930-933.
[5]	Gu Qi, Rui Fajuan, Ni Qianqian, et al. Chronic disease management in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(4): 457-459.
[6]	Fang Shanshan, Du Mingqiao, Wang Yue. Will the hypopituitarism lead to the occurrence of nonalcoholic fatty liver diseases? An preliminary study [J]. Journal of Practical Hepatology, 2023, 26(4): 504-507.
[7]	Qiu Liying, Wang Yingchun. Nonalcoholic fatty liver diseases and the intestinal microecology: Current state of the art, controversies, and perspectives [J]. Journal of Practical Hepatology, 2023, 26(3): 308-312.
[8]	Zhan Qirui, Duan Taimei, Yan Jie. Changes of serum amyloid A, plasma heme oxygenase-1 and bone morphogenetic protein 9 levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(3): 348-351.
[9]	Su Peihua, Song Meifang, Zhao Caiyan. Is the incidence of hepatocellular carcinoma increased in patients with chronic hepatitis B and nonalcoholic fatty liver diseases? [J]. Journal of Practical Hepatology, 2023, 26(3): 445-448.
[10]	Wei Li, Liu Bo, Zhao Nan, et al.. Would the coincidence of nonalcoholic fatty liver diseases impact the antiviral response to enticavir therapy in patients with chronic hepatitis B? [J]. Journal of Practical Hepatology, 2023, 26(2): 181-184.
[11]	Liu Gang, Zhang Hao, Hu Jun. Changes of serum miR-183-5p and miR-96-5p levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(2): 197-201.
[12]	Chen Fenglian, Zhu Qinglan, Zhu Lingli, et al. Different activation of peripheral blood invariant natural killer T cells and CD4⁺/CD8⁺T cells in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(1): 31-34.
[13]	Li Xiangyang, Ding Guangwei, Jin Ming. Efficacy of entecavir in treatment of patients with chronic hepatitis B and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 776-779.
[14]	Liu Yantong, Yao Yang, Lu Bo. Short-term efficacy of Heye Tiaozhi Shugan Decoction in dealing with patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 657-660.
[15]	CheDepartment of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai , Chinan Mengqi, Fan Jiangao. Brief introduction of a clinical practice guideline for the diagnosis and management of patients with nonalcoholic fatty liver diseases in USA [J]. Journal of Practical Hepatology, 2022, 25(5): 0-S16.